Atherosclerosis of Femoral Artery, Coronary Artery Diseases, Diabetes Mellitus, Type 2, Myocardial Infarction
Conditions
Keywords
atherosclerosis, development of concept, weight loss therapy
Brief summary
Study the mechanisms of atherosclerosis based on a comparative study of physical and chemical properties of lipid tissues at various localization with subsequent development of concept of treatment and prevention.
Detailed description
The chemical and physical properties of different lipids of body. The clinical part of the work is a prospective randomized comparative controlled clinical trial of patients with atherosclerotic diseases. Developed the concept of limited biological resources of the body based on the increase in the expenditure of energy reserves of the body, allowing a critical look at overweight. The role of overweight in the development of atheromatous fat was revealed. The positive results from the weight loss in patients with atherosclerotic disease were drawn. Developed the metabolic concept of atherosclerosis associated with evolutionary aging and conversion of lipids in hard atherosclerotic fat.
Interventions
DRUGConventional treatment
Lipidlowering: Atorvastatin (Liprimar) - 40mg per day. Antihypertensive: Diroton (Lisinopril, Gedeon Richter Ltd) - 10mg twice per day and Ditiazem (calcium bloker from the benthodiazepines, Lannacher, Austria) - 90mg per day. Antihyperglycemic drugs: biguanides Metformin - 0.5 g two or tree times per day, or Exenatide - 5-10 µg per day. Anti-inflammatory: TromboACC (acetylsalicylate acid) up to 2 g per day and/or Clopidogrel (thienopyridine class antiplatelet agent) - 75mg per day.
DIETARY_SUPPLEMENTWeight loss treatment
Weight loss treatment by administering a healthy very low-calorie, low-fat vegetables and salt diet and includes an adjustment and modify eating behavior and increased physical activity.
Sponsors
Ministry of Health, Kazakhstan
Nazarbayev University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
26 Years to 70 Years
Healthy volunteers
Yes
Inclusion criteria
* written informed consent form * dyslipidemia (HDL \<1.0 mmol / l, triglycerides (TG) in plasma ≥ 1,7 mmol / l or cholesterol ≥ 5,6 mmol /l) * waist circumference ≥ 94.0 cm in men or ≥ 80,0 cm in women, * BP ≥140/95 mm Hg or a patient is taking antihypertensive medications, * fasting glucose ≥ 6,1 mmol / l or the patient is taking hypoglycemic agents, * the possibility of treatment for 6 months and follow-up for 1 year
Exclusion criteria
* Absence of consent form * Non-compliance of patient to necessary recommendations. * The presence of mental illness. * Complete immobilization of a patient (paresis, and paralysis).
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| full recovery from atherosclerotic diseases | for 12 months | Regression of atherosclerosis plaque in vessel: imaging methods (GE Vivid 7 Ultrasound; GE Healthcare Worldwide USA, Michigan), and computed tomography scans (AG Siemens Somatom Emotion 6, Germany, Muenchen). Improvement of clinical condition: by measurement of clinical presence status. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| normalised laboratory and instrumental data | for 12 month | Weight loss: Tanita-SC330S Body Composition Analyzer (Tanita Corp., Tokyo, Japan) including weight (kg), body mass index (BMI, kg/m2), body composition parameters, including as fat mass (in % of total body weight and total kg), visceral fat rating (units), fat free mass (kg), total body water (in % and kg), muscle mass (in % and kg), bone mass (in % and kg), metabolic age (years), basal metabolic rate (kcal per day), and bioimpedance (Ohms). Rate of blood circulation: Dopler Ultrasound (GE Healthcare Worldwide USA, Michigan). Bone density: bone densitometry (Lunar Achilles Express Ultrasound; GE Healthcare USA, Madison). Imaging of internal organs and blood vessel diameter: computed tomography scans (AG Siemens Somatom Emotion 6, Germany, Muenchen). General clinical study of blood and urine, liver and kidneys function tests, glucose and lipids levels. Clinical condition in dynamics: clinical presence status. |
Countries
Kazakhstan
Outcome results
None listed